The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.
COVID-19
SARS-CoV-2
disease-modifying anti-rheumatic drugs
humoral response
rheumatic musculoskeletal diseases
risk of infection
seroprevalence
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
01
2022
accepted:
10
02
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Given the high occurrence of asymptomatic subsets, the true prevalence of SARS-CoV-2 infection in rheumatic patients is still underestimated. This study aims to evaluate the seroprevalence of SARS-CoV-2 antibodies in rheumatic musculoskeletal diseases (RMD) patients receiving immunomodulatory drugs. All consecutive patients with rheumatoid arthritis or spondyloarthritis receiving disease-modifying antirheumatic drugs (DMARDs) evaluated between 4th May and 16th June 2020 were included. All participants were tested for anti-SARS-CoV-2 antibodies (IgG, IgM, IgA) by ELISA and were questioned about previous COVID-19 symptoms and clinical course. Results were compared with healthy population from the same region and with a control group of healthy subjects diagnosed with confirmed COVID-19. The study population includes 358 patients. The overall prevalence of anti-SARS-CoV-2 antibodies (18.4%) was higher than prevalence rate based on swab-positivity (1.12%) or clinically suspected cases (10.6%), but consistent with seroprevalence observed in the healthy population. Among seropositive patients 58% were asymptomatic. Mean anti-SARS-CoV-2 titer was comparable with the control group. No differences in seroprevalence were observed according to age, sex, rheumatic disease and treatment with conventional, biologic or targeted synthetic DMARDs, whereas glucocorticoids and comorbidities resulted in higher seroprevalence rate. The results of this study are reassuring about the low impact of RMDs and immunomodulatory therapies on the risk and clinical course of COVID-19 and on humoral immune response to SARS-CoV-2 infection.
Identifiants
pubmed: 35360719
doi: 10.3389/fmed.2022.850858
pmc: PMC8963104
doi:
Types de publication
Journal Article
Langues
eng
Pagination
850858Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Favalli, Gobbini, Bombaci, Maioli, Biggioggero, Pesce, Favalli, Martinovic, Fabbris, Marchisio, Bandiera, Gori, Abrignani, Grifantini and Caporali.
Déclaration de conflit d'intérêts
EM is employed by Dia.Pro, Diagnostic Bioprobes Srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2255-2258
pubmed: 32337590
Rheum Dis Clin North Am. 2016 Feb;42(1):157-76, ix-x
pubmed: 26611557
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753
pubmed: 32723435
Sci Rep. 2021 Feb 23;11(1):4363
pubmed: 33623101
Lancet Rheumatol. 2020 Sep;2(9):e549-e556
pubmed: 32838307
Clin Exp Rheumatol. 2021 Sep 7;:
pubmed: 34494961
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Ann Rheum Dis. 2021 Feb;80(2):e18
pubmed: 32321723
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
Arthritis Res Ther. 2020 Dec 30;22(1):290
pubmed: 33380344
Lancet Rheumatol. 2020 Jul;2(7):e384-e385
pubmed: 32835238
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Autoimmun Rev. 2020 May;19(5):102523
pubmed: 32205186
West J Emerg Med. 2020 Sep 28;21(6):1-4
pubmed: 33052811
Semin Arthritis Rheum. 2020 Aug;50(4):564-570
pubmed: 32425260
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Nat Commun. 2020 Jul 24;11(1):3774
pubmed: 32709909